LITAF is a potential tumor suppressor in pancreatic cancer
Authors:
Open Access
- 14 December 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (3) , 3131-3142
Abstract
LITAF is a potential tumor suppressor in pancreatic cancer LITAF is a potential tumor suppressor in pancreatic cancerKeywords
This publication has 30 references indexed in Scilit:
- The 140-kD Isoform of CD56 (NCAM1) Directs the Molecular Pathogenesis of Ischemic CardiomyopathyThe American Journal of Pathology, 2013
- LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growthOncogene, 2011
- Pancreatic cancer treatment and research: an international expert panel discussionAnnals of Oncology, 2011
- SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic CancerClinical Cancer Research, 2009
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic CancerJournal of Clinical Oncology, 2009
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Molecular Markers of Early Pancreatic CancerJournal of Clinical Oncology, 2005
- PIG7/LITAF gene mutation and overexpression of its gene product in extramammary Paget's diseaseInternational Journal of Cancer, 2004
- Identification of three 11p11.2 candidate liver tumor suppressors through analysis of known human genesMolecular Carcinogenesis, 2003
- Candidate tumour suppressor genes at 11q23–q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosisOncogene, 2001